A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., published in the open-access ...
Aug 26, 2025
0
33
Antiretroviral treatments for HIV (human immunodeficiency virus) have been extremely successful in extending life expectancy and reducing transmission. But one major challenge has so far prevented researchers from developing ...
Aug 22, 2025
0
43
Why do people infected with the human immunodeficiency virus (HIV) often suffer from cardiovascular, liver, and other comorbidities? Researchers at the Center for Individualized Infection Medicine (CiiM) investigated this ...
Aug 21, 2025
0
24
The world's largest conditional cash transfer program, the Bolsa Família Program (BFP), is associated with a substantial reduction in AIDS cases and deaths, especially among brown and black women with lower income and limited ...
Aug 11, 2025
0
27
A research team from Kumamoto University has made a new discovery that reveals how the human T-cell leukemia virus type 1 (HTLV-1) silently persists in the body. Their finding potentially lays the foundation for new therapeutic ...
Aug 3, 2025
0
63
In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, eBIC director at Diamond, ...
Jul 21, 2025
0
61
The U.S. Food and Drug Administration has approved Merck's Idvynso (doravirine/islatravir), a new, once-daily, two-drug single tablet for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen ...
1 hour ago
0
0
When it comes to HIV medication, many patients think they'd prefer an occasional injection over a daily pill, but uptake remains an issue, according to a Rutgers Health-led survey. When researchers surveyed 801 people living ...
Apr 23, 2026
0
4
New data released Friday show that the President's Emergency Plan for AIDS Relief (PEPFAR) treated about the same number of people in the last quarter of 2025 as it did a year earlier in 2024.
Apr 20, 2026
0
2
A major study presented at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated biological aging in people with HIV (PWH) by nearly four years, a finding that could transform how clinicians monitor ...
Apr 19, 2026
0
10
